Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
The 15 Best Business visionaries Under 40 - 2Pick Your Favored method of transportation
- 3Jamie Dimon warns Iran war could drive inflation, interest rates higher
- 4Australia PM tries to reassure public as panic buying sees fuel demand surge 400% in some regions
- 5Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests
- A24's 'Backrooms' trailer shows endless fluorescent-lit spaces and terrifying mannequins melting into the floor
- NASA's Artemis II launch leaves Americans in awe: 'We're going back to the frickin' moon!'
- Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- 7 Heavenly Espressos, One Do You Like?
- How effective is the flu shot this year? New report shows promising results
- Step by step instructions to Pick the Ideal Authorize Internet Advertising Degree Program
- From Fledgling to Master: Self-awareness in a Side interest
- NASA unveils close-up pictures of the comet popping by from another star
- Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
